QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Pembrolizumab Classification, Mechanism, Immune Toxicity and Pharmacovigilance

Test your understanding of the concepts covered by Pembrolizumab: Classification, History, Mechanism of Action, Immune Toxicity and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best describes the immediate cellular consequence of PD-1 engagement that pembrolizumab counteracts?

Recruitment of inhibitory phosphatases that attenuate T-cell receptor and CD28 signalling Permanent deletion of antigen-specific T-cell clones from the circulation Activation of complement on the surface of tumour cells Direct phosphorylation of tumour-cell growth receptors

Question 2 of 10 Which case is most likely to contain an important medication-use error specific to pembrolizumab lifecycle management?

A report that records the tumour histology and treatment line A report involving confusion between fixed and weight-based dosing, or selection of the wrong intravenous or subcutaneous presentation A report that documents baseline organ function before treatment A report that includes the date of every treatment cycle

Question 3 of 10 Why does a prior or current solid-organ transplant materially affect assessment of pembrolizumab exposure?

Checkpoint blockade can disrupt transplant tolerance and precipitate graft rejection Transplant recipients are protected from immune-mediated toxicity by chronic immunosuppression Pembrolizumab selectively improves graft survival through PD-1 blockade Transplant history is relevant only to product quality, not clinical safety

Question 4 of 10 Why is myocarditis with concurrent myositis or a myasthenia-like syndrome a high-priority safety concern?

The overlap reliably indicates benign, self-limiting muscle inflammation Neuromuscular weakness may precede cardiac or respiratory deterioration, and myocarditis can be rapidly fatal Myositis prevents cardiac involvement by reducing immune-cell trafficking The combination is relevant only for determining tumour response, not acute safety management

Question 5 of 10 A case is closed when corticosteroids are started, although the patient's outcome and taper are unknown. What is the main pharmacovigilance deficiency?

The case lacks information needed to assess response, chronicity, relapse during taper and long-term sequelae The case is complete because treatment initiation defines the final outcome Steroid information is irrelevant once pembrolizumab is interrupted Only the initial adverse-event term is needed for regulatory assessment

Question 6 of 10 What is the most accurate implication of pembrolizumab blocking both PD-L1 and PD-L2 interaction with PD-1?

It removes one inhibitory receptor-ligand pathway while leaving the PD-1 receptor available for the other ligand It prevents engagement of the targeted inhibitory receptor by either of its principal ligands It directly stimulates T-cell receptor signalling without a requirement for antigen or co-stimulation It eliminates all immunosuppressive pathways within the tumour microenvironment

Question 7 of 10 Which regulatory interpretation is most appropriate when evaluating a pembrolizumab case across time?

The indication, biomarker requirements and presentation can be assumed to remain unchanged after initial authorisation Current product-specific information should be checked because indications, combinations, formulations and toxicity-management instructions evolve A historical clinical-trial protocol always takes precedence over current product information An EU authorisation automatically makes all indications and administration procedures identical worldwide

Question 8 of 10 Which finding most strongly supports the need for continued surveillance after the final pembrolizumab dose?

Immune-mediated events can emerge or persist after discontinuation, and durable immune effects may outlast measurable drug exposure All adverse reactions necessarily occur during the infusion Pembrolizumab has no pharmacodynamic effects after the last dose Post-treatment follow-up is relevant only for tumour efficacy

Question 9 of 10 A patient develops new pulmonary infiltrates during pembrolizumab treatment. Which approach best reflects the article's recommended reasoning?

Diagnose pneumonitis immediately because any infiltrate during checkpoint therapy is immune-mediated Exclude or assess infection, tumour progression, pulmonary embolism, heart failure and radiation injury while characterising imaging and oxygenation Stop all diagnostic investigations once corticosteroids are prescribed Attribute the finding exclusively to prior radiation regardless of timing or CT pattern

Question 10 of 10 Why should pharmacovigilance analyses be stratified by tumour type, regimen and indication when evaluating pembrolizumab safety signals?

These factors can alter patient characteristics, concomitant therapy, monitoring intensity, exposure duration and event attribution Stratification is needed only to make the database easier to search Tumour type and regimen have no influence on observed adverse-event patterns Stratification eliminates the need to assess individual case narratives

QPPV.com

Professional Knowledge Assessment: Pembrolizumab Classification, Mechanism, Immune Toxicity and Pharmacovigilance

Cookie Settings